BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32207204)

  • 1. New prognostic model for synchronous metastatic renal cell carcinoma.
    Naito S; Kato T; Ichiyanagi O; Narisawa T; Kurokawa M; Yagi M; Ushijima M; Ozawa M; Kanno H; Kurota Y; Fukuhara H; Kuboki Y; Yamagishi A; Sakurai T; Nishida H; Yamanobe T; Tsuchiya N
    Int J Urol; 2020 May; 27(5):448-456. PubMed ID: 32207204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.
    Klatte T; Patard JJ; de Martino M; Bensalah K; Verhoest G; de la Taille A; Abbou CC; Allhoff EP; Carrieri G; Riggs SB; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    J Urol; 2008 May; 179(5):1719-26. PubMed ID: 18343437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
    J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
    Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
    J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
    Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
    Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
    Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
    N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.
    Hofmann HS; Neef H; Krohe K; Andreev P; Silber RE
    Eur Urol; 2005 Jul; 48(1):77-81; discussion 81-2. PubMed ID: 15967255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.
    Daugherty M; Daugherty E; Jacob J; Shapiro O; Mollapour M; Bratslavsky G
    Urol Oncol; 2019 Mar; 37(3):182.e9-182.e15. PubMed ID: 30528396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
    J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma.
    Cho DS; Kim SI; Choo SH; Jang SH; Ahn HS; Kim SJ
    Scand J Urol; 2016 Jun; 50(3):186-91. PubMed ID: 26878156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.
    Kim SH; Suh YS; Lee DE; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    Oncotarget; 2017 Nov; 8(55):93633-93643. PubMed ID: 29212178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.